We back great science and enable novel solutions

Accelerator Life Science Partners (ALSP) is a US and Singapore-based early-stage life science accelerator and investment firm that creates and builds biotech companies based on innovative science.

The company catalyses the development and commercialisation of breakthrough biotech innovations by providing a holistic toolkit and leveraging its network and entrepreneurial expertise to accelerate the establishment and operation of early-stage biotech companies.

Allay Therapeutics is a US and Singapore-based biotech company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians.

The company’s proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates which provide pain relief within a targeted site over weeks.

Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation.

Automera aims to leverage its unique understanding of autophagy, drug development capabilities, and access to quantum chemistry and generative AI-enabled insights to enhance its drug development programs. Automera’s AUTAC platform has broad potential across cancer and other disease areas, with oncology being the initial lead program.

The company was founded by co-founders Associate Professor Michael Lazarou, Loong Wang and Taiyang Zhang at Talo Labs Pte Ltd.

Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics’ lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience.

Cirrus Therapeutics is a privately held ocular immunology-focused biotech revolutionizing the treatment of age-related macular degeneration (AMD) and other chronic blinding diseases with groundbreaking cell and gene therapies to preserve sight, extend ocular healthspan, and enable a better quality of life as people age. Our lead program is a preclinical stage, novel adeno-associated virus (AAV) ocular gene therapy designed to potentially reverse an underlying cause of dry AMD: loss of IRAK-M protein, a key immune regulator expressed in retinal cells. Our investor syndicate includes ClavystBio, Polaris Partners and SEEDS.

CoVBio is developing booster vaccines and therapeutics that are effective against variants of SARS-2 beta coronavirus.

The company’s booster pan-sarbecovirus vaccine will protect against future variants and future crossovers of related coronaviruses from animals to humans.

CovBio was acquired by Leyden Labs in 2024.
For more information, please view the press release.

Droia is a specialist biotech investor focusing on companies that develop precision therapeutics for oncology and genetic disease. Droia invests globally in newly founded through early clinical-stage companies that apply novel science and innovative technologies to bring drug candidates to patients suffering high unmet medical needs. With its team of seasoned scientists, entrepreneurs and investment professionals, Droia has been building biotech companies at the forefront of innovation and development since 2014.

Engine Biosciences is a Singapore and US-based company that develops precision medicine-based therapies for cancer and other diseases, using machine learning and large-scale experimental biological data generation and testing to decipher complex genetic networks.

The company’s proprietary technology platforms seek to integrate vast and differentiated human and disease datasets, machine learning, combinatorial genetics experiments, and in-house drug discovery to identify and develop promising drug targets for specific patient genetic and treatment contexts. Engine Biosciences’ technologies enable researchers and drug developers to feed and advance their therapeutics pipelines to treat unmet medical needs across a range of diseases.

Eyexora is a global ophthalmology company pioneering a hub-and-spoke model to accelerate innovation in eye care. By centralizing scientific, clinical, regulatory, and commercial expertise, Eyexora advances a diversified pipeline of therapies and devices through focused subsidiaries, to reduce risk, improve efficiency, and scale impact.

Founded by leaders with decades of ophthalmology experience and a track record of more than 30 successful company and product launches, Eyexora partners with clinician-scientists and research institutes worldwide to bring transformative eye care solutions to patients faster and smarter.

Hummingbird Bioscience is a data-driven multidisciplinary team discovering and developing transformative precision biotherapeutics for hard-to-treat diseases. Leveraging computational and systems biology, the company’s proprietary approach has yielded wholly owned clinical-stage drug candidates now in development.

Leyden Labs is working to free people from the threat of respiratory viruses. The company is leveraging its Mucosal Protection Platform to develop a portfolio of candidates aimed at providing protection against influenza, coronaviruses, and other respiratory viruses through a new class of broadly protective nasal sprays.

Lightstone Ventures is a global venture capital firm investing in early stage, therapeutic-oriented companies across the life science spectrum, as well as opportunistic late-stage companies.

Operating in Menlo Park, Boston, Ireland and Singapore, the company aims to empower founders to bring innovative therapeutics to patients.

MediSix Therapeutics is a Singapore-based immune engineering company that develops novel cellular therapies to address T-cell malignancies and autoimmune diseases.

The company has developed a technology platform on genetic engineering that utilises proprietary immune engineering approaches to generate T-cells for effective immune cell therapies.

Founded with a focus on supporting biotech innovation, NSG BioLabs offers state-of-the-art equipment, efficient operations, capital efficiency, the expertise of world-class teams and global networks to assist life sciences companies. The conducive R&D environment contains fully-equipped, certified BSL-2 laboratory and office infrastructure across 35,000 sq ft in the prime location of Biopolis in Singapore.

By providing access to high-quality infrastructure, its extensive partner network, community, and value-add benefits, NSG BioLabs ensures that companies, ranging from emerging biotech startups to multinational companies, can rapidly and efficiently execute on their cutting-edge research and development ecosystem in Singapore, leading to the innovation of revolutionary technologies and products that translate into breakthrough biotech ventures and impact for patients.

Nuevocor is a Singapore-based biotech company developing targeted gene therapies to restore heart function through a deep understanding of fundamental mechanisms underlying genetic cardiac diseases.

The company is founded and advised by leaders in mechanobiology, cardiac disease and gene therapy. Its lead candidate treats the underlying biomechanical cause of LMNA dilated cardiomyopathy, while its PrOSIA mechanobiology platform enables target discovery and validation for additional genetic cardiomyopathies.

Paratus Sciences is committed to improving human health and health security by understanding the exceptional biology of bats. The company is focused on identifying and developing human therapeutics for diseases of high unmet need, including inflammation, virology, metabolism, oncology, and autoimmune disorders.

Polaris Partners aims to accelerate the commercial and therapeutic potential of disruptive healthcare and technology companies across the innovation cycle. By partnering with passionate entrepreneurs with transformational science, Polaris’ Fund fosters creation and growth of companies through an active investment model.

Quilt is a generative AI-powered platform to create and discover fast-acting, personalized interventions to support individuals during moments of stress, anxiety, insomnia, low mood, and other challenges they may face. Through its mobile-based digital biomarkers, Quilt also identifies and connects at-risk individuals to relevant care services and products.

Remiges Ventures is a venture capital firm with offices in Japan and the United States, focusing on company creation based on innovative science and seed products, and manages the company formation process by its incubator, RDiscovery to move the product development towards the Series A stage.

Respiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare’s care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA).

Sunbird Bio is developing protein-based diagnostic tests that provide unprecedented insights to enable earlier, more accurate diagnosis and treatment of Alzheimer’s disease, other neurological disorders and early-stage cancer.

The company's APEX technology is the first test that has demonstrated ability to detect – with a simple blood draw – low levels of the aggregated amyloid beta (Aβ) proteins that signal the presence of Alzheimer’s disease. APEX has significant promise for use in other neurological disorders as well. Its pipeline of innovative, non-invasive technologies will empower researchers and clinicians with unparalleled insights not available from current tests.